Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
dostarlimab (Jemperli) (1 trial)
neratinib maleate (nerlynx) (1 trial)
niraparib (zejula) (1 trial)
sargramostim (leukine) (1 trial)
talimogene laherparepvec (Imlygic) (1 trial)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Melanoma (Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Trials (4 total)
Trial APIs (5 total)